In today's economic climate, it is more challenging than ever for pharmaceutical and biotech companies to deliver on shareholder value.
PwC is well positioned to assist you with all of your transaction needs.
The loss of patent protections and a shortfall in the pipeline to replace lost sales, combined with the general decline in return on research & development and sales and marketing, has left companies searching for alternative methods of delivering maximum returns to shareholders.
Many are looking to transactions such as mergers & acquisitions, divestitures, and licensing/collaborations to enhance value during these challenging times.
Recent transaction activity in the industry includes:
We have a strong track record of working with clients across all segments of the pharmaceutical and life sciences industry. Our specialists offer a full range of services, from inception to post-deal integration. And our global network, in combination with our in-depth industry knowledge, enables us to be constantly in touch with the markets and to spot opportunities and assemble teams to execute a deal as the need arises.
Our professionals are able to help not only with the accounting and tax considerations that deals create, but with a wide range of planning and integration concerns related to operational, systems and regulatory issues.